



## CDC Health Advisory


### Urgent Need to Increase Immunization Coverage for Influenza, COVID-19, and RSV Immunizations and Use of Authorized/Approved Therapeutics in the Setting of Increased Respiratory Disease Activity During the 2023 – 2024 Winter Season.

December 19, 2023

The CDC issued a health advisory on 12/14/23 alerting healthcare providers to increasing influenza, SARS-CoV-2, and RSV activity and low vaccination rates against these pathogens. CDC urges providers to recommend and offer immunizations and to offer antiviral medication to eligible patients. The CDC has created communication tools including a [Conversation Guide for Healthcare Providers](#) and [Healthcare Provider Toolkit](#) to support providers' efforts to protect their patients this respiratory virus season.

Below, we provide additional information on influenza, COVID-19, and RSV activity and immunizations in Los Angeles County.

Percent of Respiratory Specimens Testing Positive by Viral Etiology  
Los Angeles County Sentinel Surveillance Laboratories  
2023-2024 Influenza Season



Source: LACDPH [Resp Watch](#)

### Influenza:

- In Los Angeles County, the percentage of specimens testing positive for influenza at sentinel surveillance sites continues to increase and is currently at 14.2%. In addition, there continues to be an increase in influenza hospitalizations. Influenza-like illness accounts for a significant proportion of emergency department visits in Los Angeles County, particularly among children 0-17 years of age.
- As of 11/30/2023 we estimate that this season's flu vaccine coverage in Los Angeles County was 22% in all persons ages 6 months and older and 51% in persons ages 65 years and older.

## COVID-19:

- As of 12/15/23 in Los Angeles County, the percentage of specimens testing positive for COVID-19 at sentinel surveillance sites remains high and is currently at 10.3%. COVID-positive hospitalizations have been increasing. For the week ending 12/9/23, there was an average of 524 hospitalizations a day.
- As of 12/10/23 we estimate that coverage with the updated 2023-2024 COVID-19 vaccine in Los Angeles County is 9% in all persons ages 6 months and older and 23% in persons ages 65 years and older.

## RSV:

- In the week ending 12/9/23, 12.5% of all specimens tested at sentinel surveillance laboratories in Los Angeles County were positive for RSV.
- As of 12/12/23 we estimate that that in Los Angeles County RSV vaccine coverage is 6.5% for persons ages 60 years and older, and 8% for females ages 15-45 years who were presumed to be pregnant. We estimate that only 6.7% of eligible infants have received nirsevimab.
- Immunizations are now available to prevent RSV in [infants](#) (either through maternal vaccination and directly to infants) and [adults over 60](#) years. RSV vaccines (Abyrsvo and Arexvy) are available at pharmacies and providers offices and are covered by Medi-Cal, MediCare Part D, and most private insurance companies. Infants who are uninsured or on Medi-Cal [can receive nirsevimab](#) at our Los Angeles County Department of Public Health clinics for free.

For more information regarding respiratory virus activity in Los Angeles County, please refer to LACDPH [Resp Watch](#).

We encourage all providers to continue to contact their patients to recommend and offer these immunizations.

## Medications

All providers should offer therapeutics to eligible patients. Both influenza and COVID-19 antiviral medications are underused but can assist in decreasing hospitalizations if used promptly in high-risk individuals. Since Paxlovid and Lagevrio have transitioned to the commercial market, patient assistance programs are now in place to assist with access to these products. Information about these programs can be accessed at [paxlovid.com/paxcess](https://paxlovid.com/paxcess) and [merckhelps.com/](https://merckhelps.com/). Please see the [12/18/23 CDPH Health Advisory](#) for additional guidance regarding COVID-19 Therapeutics and services. Patients can still access COVID-19 therapeutics and telehealth services for free through the Los Angeles County Dept of Public Health at 1-833-540-0473. Providers inquiring about access to any remaining US Government supplies can reach out to [DPH-Therapeutics@ph.lacounty.gov](mailto:DPH-Therapeutics@ph.lacounty.gov).

Please refer to the CDC communication for additional information regarding immunizations, antiviral medications, reporting of MIS-C, and resources for preparing your patients for the fall and winter virus season.

Read the CDC communication [online](#) or below.

---

To view this and other communications or to sign-up to receive LAHANs, please visit [ph.lacounty.gov/lahan](https://ph.lacounty.gov/lahan).

**This is an official**  
**CDC HEALTH ADVISORY**

Distributed via the CDC Health Alert Network  
December 7, 2023, 10:45 AM ET  
CDCHAN-00501

## **Mpox Caused by Human-to-Human Transmission of Monkeypox Virus with Geographic Spread in the Democratic Republic of the Congo**

### **Summary**

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to notify clinicians and health departments about the occurrence, geographic spread, and sexually associated human-to-human transmission of Clade I Monkeypox virus (MPXV) in the Democratic Republic of the Congo (DRC). MPXV has two distinct genetic clades (subtypes), and cases of Clade I MPXV have not been reported in the United States at this time (a clade is a broad grouping of viruses that has evolved over decades and is a genetic and clinically distinct group). However, clinicians should be aware of the possibility of Clade I MPXV in travelers who have been in DRC. Clinicians should notify their [state health department](#) if they have a patient with mpox-like symptoms, which may include a diffuse rash and lymphadenopathy, and recent travel to DRC. Clinicians should also submit lesion specimens for clade-specific testing for these patients.

Vaccines (e.g., JYNNEOS, ACAM2000) and other [medical countermeasures](#) (e.g., tecovirimat, brincidofovir, and vaccinia immune globulin intravenous) are available and expected to be effective for both Clade I and Clade II MPXV infections. However, vaccination coverage in the United States remains low, with only one in four people who are [eligible to receive the vaccine](#) having received both doses of JYNNEOS. CDC recommends that clinicians encourage vaccination for patients who are eligible.

### **Background**

MPXV has two distinct genetic clades (subtypes of MPXV), I and II, which are endemic to central and west Africa, respectively. Clade IIb MPXV has been associated with the 2022-23 global outbreak that has predominately affected gay, bisexual, and other men who have sex with men (MSM). Clade I MPXV is capable of human-to-human spread but has previously been associated with non-sexual routes of transmission; and Clade I has previously been observed to be more transmissible and to cause more severe infections than Clade II. Since January 1, 2023, DRC has reported 12,569 suspected mpox cases (i.e., clinically diagnosed but not laboratory-confirmed) and 581 deaths (5% of suspected mpox cases). This is a substantial increase from the median 3,767 suspected [mpox cases reported annually in DRC](#) during the years 2016-2021. Clade I MPXV has been confirmed among cases for which testing was conducted. A recent [World Health Organization \(WHO\) report](#) noted that mpox cases in 2023 have been reported in more DRC provinces than in previous years (i.e., 22 of 26 provinces). This includes cases in urban settings where mpox does not normally occur (Kinshasa and South Kivu Province). In two provinces, outbreaks of Clade I MPXV associated with sexual contact, including among MSM, have been reported for the first time in DRC. Mpox vaccination is not generally available in DRC.

As part of surveillance for viral variants in the United States, CDC has tested a subset of positive MPXV or orthopoxvirus cases from commercial and state laboratories and performed clade-specific testing for 150 cases in 2023 (~12% of U.S. cases); no Clade I MPXV infections have been detected thus far. There are no direct commercial passenger flights from DRC to the United States, and the current threat for Clade I MPXV in travelers remains low. [Clade II MPXV infections continue to occur in the United States](#). CDC encourages U.S. clinicians to continue to be alert for patients presenting with [lesions consistent with mpox](#). Suspicion for Clade I MPXV should be high for people with travel to DRC within 21 days of illness onset, and clade-specific testing of MPXV should be performed in specimens from suspect mpox case-patients who report recent travel to DRC.

Most patients who have recovered from mpox (including infection with Clade II MPXV) or have been vaccinated with JYNNEOS or ACAM2000 are expected to have cross-protection to Clade I MPXV. However, clinicians are recommended to consider mpox as a possible diagnosis if a consistent clinical presentation occurs, even in those who are vaccinated or were [previously diagnosed with mpox](#).

## **Recommendations for Clinicians and Health Departments**

### ***Diagnosis***

Clinicians should continue to consider mpox when evaluating the cause of rashes. [Mpox lesions](#) may be small, firm and rubbery, deep-seated, and well-circumscribed, or they may be large, with diffuse, centrifugal lesion distribution. Lymphadenopathy may also be present. During the Clade II outbreak, among people with severe immunocompromise (e.g., due to advanced HIV with CD4 <200 or solid organ transplantation), rash lesions have generally been diffusely distributed, appearing large, necrotic, and fungating (i.e., appearing or progressing like a fungal infection). Consideration of mpox should be heightened in patients who have [epidemiologic characteristics](#) supportive of mpox (including travel from mpox-endemic regions such as DRC within 21 days of illness onset).

For patients with travel to DRC within 21 days of illness onset, CDC recommends that clinicians pursue MPXV clade-specific testing starting with a [consultation with state health departments](#) for testing options (e.g., molecular testing or genetic sequencing). CDC recommends clinicians follow [specimen collection guidelines](#) (including collection of two swabs per lesion) to ensure specimen availability for testing. Unroofing or aspiration of lesions or otherwise using sharp instruments for mpox testing is not recommended due to the risk of sharps injury. If clade-specific testing is not available in a jurisdiction, [specimen submission](#) to CDC is strongly encouraged; specimen submission to CDC can be coordinated through your state or local health department.

### ***Treatment and Prevention***

[Medical countermeasures](#) (e.g., tecovirimat, brincidofovir, and vaccinia immune globulin intravenous) that have been used during the ongoing Clade II MPXV outbreak in the United States are expected to be effective for Clade I MPXV infections. Public health authorities should be consulted promptly for any mpox cases for which severe manifestations might occur. Tecovirimat is available through the [STOMP trial and Investigational New Drug \(IND\) protocol](#).

Vaccination with JYNNEOS or ACAM2000 or prior MPXV infection should provide antibodies that will provide cross-protection to other orthopoxviruses, including Clade I MPXV. [The Advisory Committee on Immunization Practices \(ACIP\)](#) recommends that people ≥18 years of age with [risk factors for mpox](#) be vaccinated, before an exposure, with two doses of the JYNNEOS vaccine 28 days apart unless they were previously infected with mpox or already received two doses. There is no recommendation regarding vaccination for travelers who do not otherwise meet the eligibility criteria. Eligible patients who have only received one dose of the JYNNEOS vaccine should receive the second dose as soon as possible, regardless of the amount of time that has elapsed since the first dose.

### ***Infection Prevention and Control***

[Healthcare personnel](#) who evaluate and provide care to patients with mpox and [laboratory personnel](#) should continue to follow existing CDC guidance on infection prevention and control for mpox. These are effective in minimizing transmission.

### **Recommendations for Diagnostic Testing**

Public health authorities are being encouraged to enhance surveillance efforts to aid detection of Clade I MPXV should it occur in the United States. All [Laboratory Response Network](#) laboratories and commercial laboratories using CDC's non-variola orthopoxvirus (NVO) polymerase chain reaction (PCR) test are requested to continue submitting duplicate specimens to CDC from all patients with positive NVO PCR test results for routine MPXV clade-specific testing. This will assist with national surveillance efforts. Specimens collected from patients who traveled to DRC should be sent to CDC as expeditiously as possible.

Some non-CDC laboratories may also have options (e.g., molecular testing or genetic sequencing) available for clade-specific testing. Laboratories should alert their [state health department](#) and CDC ([poxvirus@cdc.gov](mailto:poxvirus@cdc.gov)) if they detect Clade I MPXV. If clade-specific testing is not available in a jurisdiction, [specimen submission](#) to CDC is encouraged; specimen submission to CDC can be coordinated through your state or local health department.

All regulations should be followed for packaging and [transporting specimens](#) from suspect mpox patients as [Category B](#) for diagnostic testing. Please refer to the most recent CDC guidance for [submitting specimens to CDC](#). Specimens that cannot be accepted for clinical testing under Clinical Laboratory Improvement Amendments (CLIA) will be redirected for surveillance purposes and tested, helping to provide critical data on the mpox clade(s) circulating in the United States. Specimens tested under surveillance will not have patient reports sent back to the submitter.

### Recommendations for the Public

There is no known risk for Clade I MPXV in the United States at this time. CDC continues to recommend people with [risk factors for mpox](#) be vaccinated with two doses of the JYNNEOS vaccine. If someone with risk factors for mpox has only received one dose, they should receive a second dose as soon as possible because two doses provide greater protection.

CDC has issued a [Travel Health Notice](#) for people traveling to DRC. People who have traveled to DRC should seek medical care **at once** if they develop a new, [unexplained skin rash \(lesions on any part of the body\), with or without fever and chills](#), and **avoid contact with others**.

### For More Information

- CDC Poxvirus and Rabies Branch: [poxvirus@cdc.gov](mailto:poxvirus@cdc.gov) or for emergencies, CDC's 24/7 Emergency Operations Center (EOC): 770-488-7100. General inquiries: CDC-INFO (1-800-232-4636).
- State and Local Health Department Contacts: [After Hours/Epi-on-Call Contact Lists - Council of State and Territorial Epidemiologists \(cste.org\)](#)
- Mpox Clinical Recognition and Vaccine Information for Healthcare Providers: [Information For Healthcare Professionals | Mpox | Poxvirus | CDC](#)
- Mpox Information for the Public: [Your Health | Mpox | Poxvirus | CDC](#)
- Biosafety and Select Agent Considerations: [Laboratory Procedures | Mpox | Poxvirus | CDC](#)
- Diagnostic Specimen Packaging and Shipping: [Transporting Infectious Substances Safely.pdf \(dot.gov\)](#)

### References

Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, et al. Clade I-Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo. *Emerg Infect Dis*. Published online November 29, 2023. [doi:10.3201/eid3001.231164](https://doi.org/10.3201/eid3001.231164)

McCollum AM, Shelus V, Hill A, et al. Epidemiology of Human Mpox - Worldwide, 2018-2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(3):68-72. Published 2023 Jan 20. [doi:10.15585/mmwr.mm7203a4](https://doi.org/10.15585/mmwr.mm7203a4)

Ulaeto D, Agafonov A, Burchfield J, et al. New nomenclature for mpox (monkeypox) and monkeypox virus clades. *Lancet Infect Dis*. 2023;23(3):273-275. [doi:10.1016/S1473-3099\(23\)00055-5](https://doi.org/10.1016/S1473-3099(23)00055-5)

World Health Organization. Mpox (monkeypox) in the Democratic Republic of the Congo. November 23, 2023. <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493>

*The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national and international organizations.*

**Categories of Health Alert Network messages**

- Health Alert** Conveys the highest level of importance about a public health incident.
- Health Advisory** Provides important information about a public health incident.
- Health Update** Provides updated information about a public health incident.